Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase (HDAC) inhibitors are emerging anti-tumor agents with potential in breast cancer therapy.
• HDAC inhibitors influence estrogen receptor (ER) and progesterone receptor expression differently in ER-positive and ER-negative breast cancer cells.

Purpose of the Study:

• To review the interplay between estrogen signaling and HDACs in breast cancer.
• To examine the impact of HDAC inhibitors on this relationship and their synergy with anti-estrogen therapies.
• To discuss the clinical potential of combining HDAC inhibitors with anti-estrogen treatments.

Main Methods:

• Literature review of studies on HDAC inhibitors, estrogen signaling, and breast cancer.
• Analysis of preclinical data on the efficacy of combined HDAC inhibitor and anti-estrogen therapy.
• Summary of ongoing clinical trials investigating this therapeutic approach.

Main Results:

• HDAC inhibitors can down-regulate ER in ER-positive cells and restore ER expression in ER-negative cells.
• HDAC inhibitors modulate progesterone receptor expression.
• In preclinical models, HDAC inhibitors potentiate and restore the efficacy of anti-estrogen therapy.

Conclusions:

• Despite differential effects on ER, HDAC inhibitors synergize with anti-estrogens to inhibit tumor growth.
• Clinical trials are underway to evaluate the combination of HDAC inhibitors and anti-estrogen therapy for breast cancer.
• This combination represents a promising new therapeutic strategy for breast cancer treatment.